Literature DB >> 11683235

Progress in the use of biological assays during the development of biotechnology products.

A R Mire-Sluis1.   

Abstract

The complexity of the structure and function of many biotechnology derived products necessitates a wide range of analytical procedures to adequately characterize the product. In-depth characterization is required for the assessment of several criteria vital to the success of product development such as consistency, purity, stability, and potency. More recently, the concern over the immunogenicity of biologics has increased the need to develop assays to detect neutralizing anti-product antibodies. Although many physicochemical tests are available to characterize the structure of a protein and detect the presence of contaminants, they provide little, if any, information regarding biological potency or the neutralizing capacity of antibody responses in immunogenicity studies. There is a continual need to refine biological assays to increase their accuracy and reproducibility, in particular to replace in vivo bioassays with appropriate in vitro assays. There have also been several recent technological developments that could lead to more rapid and reproducible bioassays.

Mesh:

Year:  2001        PMID: 11683235     DOI: 10.1023/a:1013067424248

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

1.  Bioassays of gonadotropins.

Authors:  S Christin-Maitre; C Vasseur; B Fauser; P Bouchard
Journal:  Methods       Date:  2000-05       Impact factor: 3.608

2.  Control and statistical analysis of in vitro reporter gene assays.

Authors:  N J Plant; M Ogg; M Crowder; G G Gibson
Journal:  Anal Biochem       Date:  2000-02-15       Impact factor: 3.365

Review 3.  BIACORE: an affinity biosensor system for characterization of biomolecular interactions.

Authors:  M Malmqvist
Journal:  Biochem Soc Trans       Date:  1999-02       Impact factor: 5.407

4.  Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics.

Authors:  A R Mire-Sluis
Journal:  Dev Biol (Basel)       Date:  2002

5.  Quality considerations for recombinant DNA-derived biological therapeutic products: a control perspective on cytokines.

Authors:  A Mire-Sluis; R Thorpe
Journal:  BioDrugs       Date:  1999-06       Impact factor: 5.807

Review 6.  WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis and as therapeutic agents.

Authors:  A R Mire-Sluis; R G Das; A Padilla
Journal:  J Immunol Methods       Date:  1998-07-01       Impact factor: 2.303

7.  Laboratory protocols for the quantitation of cytokines by bioassay using cytokine responsive cell lines.

Authors:  A R Mire-Sluis; R Thorpe
Journal:  J Immunol Methods       Date:  1998-02-01       Impact factor: 2.303

8.  Use of a dual firefly and Renilla luciferase reporter gene assay to simultaneously determine drug selectivity at human corticotrophin releasing hormone 1 and 2 receptors.

Authors:  S J Parsons; S A Rhodes; H E Connor; S Rees; J Brown; H Giles
Journal:  Anal Biochem       Date:  2000-06-01       Impact factor: 3.365

9.  A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy.

Authors:  J E Thompson; T J Vaughan; A J Williams; J Wilton; K S Johnson; L Bacon; J A Green; R Field; S Ruddock; M Martins; A R Pope; P R Tempest; R H Jackson
Journal:  J Immunol Methods       Date:  1999-07-30       Impact factor: 2.303

10.  Evaluation of assay designs for assays using microtitre plates: results of a study of in vitro bioassays and immunoassays for tumour necrosis factor (TNF).

Authors:  R E Gaines Das; A Meager
Journal:  Biologicals       Date:  1995-12       Impact factor: 1.856

View more
  6 in total

1.  Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor.

Authors:  Mercedes Cedeño-Arias; Javier Sánchez-Ramírez; Rancés Blanco-Santana; Enrique Rengifo-Calzado
Journal:  Sci Pharm       Date:  2011-07-03

2.  Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach.

Authors:  Alexander N Shikov; Olga N Pozharitskaya; Natalia M Faustova; Vera M Kosman; Valery G Makarov; Ebrahim Razzazi-Fazeli; Johannes Novak
Journal:  Mar Drugs       Date:  2019-10-11       Impact factor: 5.118

3.  A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT.

Authors:  Zhihao Fu; Hongchuan Liu; Lan Wang; Chuanfei Yu; Yalan Yang; Meiqing Feng; Junzhi Wang
Journal:  Acta Pharm Sin B       Date:  2021-09-17       Impact factor: 11.413

4.  A novel bioassay for the activity determination of therapeutic human brain natriuretic peptide (BNP).

Authors:  Lei Yu; Chunming Rao; Xinchang Shi; Yonghong Li; Kai Gao; Xuguang Li; Junzhi Wang
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

5.  Detection of Infertility-related Neutralizing Antibodies with a Cell-free Microfluidic Method.

Authors:  Klaus Eyer; Katharina Root; Pascal E Verboket; Petra S Dittrich
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

Review 6.  Biopotency Assays: an Integrated Application to Quality Control of Chinese Materia Medica.

Authors:  Yin Xiong; Dan Yan; Jia-Bo Wang; Xiao-He Xiao
Journal:  Chin Herb Med       Date:  2014-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.